As we begin June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. We're currently running a 40% OFF ASCO sale, learn more here.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move | YTD Move |
|---|---|---|
All BPIQ Companies | -3.40% | -47.81% |
CAR-T Companies | -1.97% | -52.34% |
Gene Editing Companies | 0.70% | -58.1% |
XBI | -5.87% | -40.13% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week and month
EHA
EHA started yesterday and runs through Monday. See our separate EHA post including info on clinical trials and big stock moves.
Biggest positive move
#COGT +81.8% Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Biggest negative move
#PRAX -79.2% Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder
Additional weekly big moves
#DBVT +74.7% DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
#BMEA +57.9% Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
#ALT +57.2%
#CRDF +50.7%
#ACXP +47.3%
#ATHX +45.9% Athersys Hosting KOL Panel Event to Discuss TREASURE Data
#NYMX +39.5%
#WVE +36%
#ONCR +35.4%
#CFRX +34% ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
#MRTX +33.3% New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
#MCRB +28.8% Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.
#ANNX +24.9% Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease.
#BLUE +21.2% bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting.
#ALDX +12.2% Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
#VERU +16.8% Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
#TLSA +11.1% Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
#ALLO +10.2% Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
#RNLX -13.1% KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
#VRNA -14% Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
#APVO -14.4% Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
#BPMC -19% Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis
#RLYB -23%
#PMVP -21.7% PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
#ICPT -22.6% Intercept Provides Update on NASH Regulatory Timeline
#MRNS -24.4% Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
#DTIL -24.6% Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
#ARCT -24.6%
#IMVT -25.2% Fourth Quarter and Full Year 2022 Financial Results Conference Cal
#PMVP -30.4% PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
#HUMA -33.2% Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
#FULC -38.3% Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
#RIGL -60.2% Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
$ACAD PDUFA AdComm
$RYTM PDUFA
EHA started yesterday (6/9)
See our Separate EHA post for more details about this key annual cancer biopharma meeting
See our Big Movers post to learn about upcoming Movers throughout June and PDUFAs, after subscribing. Learn more here.
Comments